Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
29
pubmed:dateCreated
2006-7-6
pubmed:abstractText
The presentation of human leukocyte antigens (HLA) class I requires the coordinated expression of numerous components involved in antigen presentation. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing (TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2. The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter containing an interferon (IFN)-gamma-response factor element; thus, the IFN-gamma-signal strongly induces both TAP1 and LMP2 expression. Low molecular weight proteins2-deficient mice exhibited the development of uterine leiomyosarcomas. Here, the differential responsiveness to IFN-gamma of the SKN human uterine leiomyosarcomas cell line was investigated. We now identify the G871E mutation in the ATP-binding region of Janus kinases 1, suggesting that the loss of TAP1 and LMP2 induction is a defect in the earliest steps of the IFN-gamma-signal pathway, resulting in the inability of SKN cells to upregulate the antigen-processing pathway. Understanding the mechanisms by which these tumors circumvent cytokine signalling, thereby evading antitumor-specific immunity, would greatly aid the efficacy of immunotherapy for treating uterine leiomyosarcomas.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/ATP-Binding Cassette Transporters, http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Triphosphate, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Cysteine Endopeptidases, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma, http://linkedlifedata.com/resource/pubmed/chemical/JAK1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Jak1 protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Janus Kinase 1, http://linkedlifedata.com/resource/pubmed/chemical/LMP-2 protein, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/TAP1 protein, human
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0950-9232
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4016-26
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16474838-ATP-Binding Cassette Transporters, pubmed-meshheading:16474838-Adenosine Triphosphate, pubmed-meshheading:16474838-Amino Acid Substitution, pubmed-meshheading:16474838-Animals, pubmed-meshheading:16474838-Antigen Presentation, pubmed-meshheading:16474838-Antigens, Neoplasm, pubmed-meshheading:16474838-Cysteine Endopeptidases, pubmed-meshheading:16474838-Female, pubmed-meshheading:16474838-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16474838-Genes, MHC Class I, pubmed-meshheading:16474838-HeLa Cells, pubmed-meshheading:16474838-Humans, pubmed-meshheading:16474838-Immunotherapy, pubmed-meshheading:16474838-Interferon-gamma, pubmed-meshheading:16474838-Janus Kinase 1, pubmed-meshheading:16474838-Leiomyoma, pubmed-meshheading:16474838-Mice, pubmed-meshheading:16474838-Mice, Knockout, pubmed-meshheading:16474838-Point Mutation, pubmed-meshheading:16474838-Protein Binding, pubmed-meshheading:16474838-Protein Structure, Tertiary, pubmed-meshheading:16474838-Protein-Tyrosine Kinases, pubmed-meshheading:16474838-Sarcoma, pubmed-meshheading:16474838-Signal Transduction, pubmed-meshheading:16474838-Tumor Escape, pubmed-meshheading:16474838-Uterine Neoplasms
pubmed:year
2006
pubmed:articleTitle
The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
pubmed:affiliation
Department of Immunology and Infectious Diseases, Shinshu University Graduate School of Medicine, Matsumoto, Nagano, Japan. takuma-h@sch.md.shinshu-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't